Solomon, Benjamin J.Zhou, Cai CunDrilon, AlexanderPark, KeunchilWolf, JurgenElamin, YasirDavis, Hannah M.Soldatenkova, VictoriaSashegyi, AndreasLin, Aimee BenceLin, Boris K.Loong, Herbert H. F.Novello, SilviaArriola Aperribay, EdurnePérol, MauriceGoto, KoichiSantini, Fernando C.2022-02-252022-02-252021Solomon BJ, Zhou CC, Drilon A, Park K, Wolf J, Elamin Y, Davis HM, Soldatenkova V, Sashegyi A, Lin AB, Lin BK, F Loong HH, Novello S, Arriola E, Pérol M, Goto K, Santini FC. Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer. Future Oncol. 2021;17(7):763-73. DOI: 10.2217/fon-2020-09351479-6694http://hdl.handle.net/10230/52570Selpercatinib, a novel, highly selective and potent, inhibitor of RET, demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pretreated and treatment-naive RET fusion-positive non-small-cell lung cancer patients in a Phase I/II clinical trial. LIBRETTO-431 (NCT04194944) is a randomized, global, multicenter, open-label, Phase III trial, evaluating selpercatinib versus carboplatin or cisplatin and pemetrexed chemotherapy with or without pembrolizumab in treatment-naive patients with locally advanced/metastatic RET fusion-positive nonsquamous non-small-cell lung cancer. The primary end point is progression-free survival by independent review. Key secondary end points include overall survival, response rate, duration of response and progression-free survival. Clinical trial registration: NCT04194944 (ClinicalTrials.gov).application/pdfengThis work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/info:eu-repo/semantics/articlehttp://dx.doi.org/10.2217/fon-2020-0935Phase III trialRET fusion-positiveRET kinase inhibitorRET rearrangementNon-small-cell lung cancerSelpercatinibTargeted therapyinfo:eu-repo/semantics/openAccess